Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications
Guranda Chitadze, Jaydeep Bhat, Marcus Lettau, et al.
Scandinavian Journal of Immunology (2013) Vol. 78, Iss. 2, pp. 120-129
Open Access | Times Cited: 169

Showing 1-25 of 169 citing articles:

NK cells for cancer immunotherapy
Noriko Shimasaki, Amit Jain, Dario Campana
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 3, pp. 200-218
Closed Access | Times Cited: 973
Recognition of Tumors by the Innate Immune System and Natural Killer Cells
Assaf Marcus, Benjamin G. Gowen, Thornton W. Thompson, et al.
Advances in immunology (2014), pp. 91-128
Open Access | Times Cited: 346
Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma
Shu-Biao Ye, Ze-Lei Li, Dong-Hua Luo, et al.
Oncotarget (2014) Vol. 5, Iss. 14, pp. 5439-5452
Open Access | Times Cited: 315
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Weiwen Deng, Benjamin G. Gowen, Li Zhang, et al.
Science (2015) Vol. 348, Iss. 6230, pp. 136-139
Open Access | Times Cited: 224
NKG2D and Its Ligands: “One for All, All for One”
Alessandra Zingoni, Rosa Molfetta, Cinzia Fionda, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 219
Killers 2.0: NK cell therapies at the forefront of cancer control
Jonathan J. Hodgins, S. Khan, Maria M. Park, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 9, pp. 3499-3510
Open Access | Times Cited: 186
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Yoshiyuki Nakamura
Frontiers in Medicine (2019) Vol. 6
Open Access | Times Cited: 172
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments
Olivier Demaria, Laurent Gauthier, Guilhaume Debroas, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 8, pp. 1934-1942
Closed Access | Times Cited: 116
The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited
Kevin Dzobo, Dimakatso Alice Senthebane, Collet Dandara
Cancers (2023) Vol. 15, Iss. 2, pp. 376-376
Open Access | Times Cited: 94
New immune cell engagers for cancer immunotherapy
Aurore Fenis, Olivier Demaria, Laurent Gauthier, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 7, pp. 471-486
Closed Access | Times Cited: 68
Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
Andrea Gras Navarro, Andreas T. Björklund, Martha Chekenya
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 151
NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy
Dominik Schmiedel, Ofer Mandelboim
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 147
The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where
Ioannis S. Pateras, Sophia Havaki, Xenia Nikitopoulou, et al.
Pharmacology & Therapeutics (2015) Vol. 154, pp. 36-56
Open Access | Times Cited: 132
NKG2D signaling in cancer immunosurveillance
Alejandro López‐Soto, Leticía Huergo-Zapico, Andrea Acebes‐Huerta, et al.
International Journal of Cancer (2014) Vol. 136, Iss. 8, pp. 1741-1750
Open Access | Times Cited: 128
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
Zachary Davis, Daniel A. Vallera, Jeffrey S. Miller, et al.
Seminars in Immunology (2017) Vol. 31, pp. 64-75
Open Access | Times Cited: 123
Genetics, genomics, and evolutionary biology of NKG2D ligands
Raphaël Carapito, Seiamak Bahram
Immunological Reviews (2015) Vol. 267, Iss. 1, pp. 88-116
Closed Access | Times Cited: 109
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Wing Keung Chan, Siwen Kang, Youssef Youssef, et al.
Cancer Immunology Research (2018) Vol. 6, Iss. 7, pp. 776-787
Open Access | Times Cited: 101
Platelet-Leukocyte Interplay in Cancer Development and Progression
Dagmar Stoiber, Alice Assinger
Cells (2020) Vol. 9, Iss. 4, pp. 855-855
Open Access | Times Cited: 85
Research Progress on NK Cell Receptors and Their Signaling Pathways
Yingying Chen, Dan Lu, Alexey V. Churov, et al.
Mediators of Inflammation (2020) Vol. 2020, pp. 1-14
Open Access | Times Cited: 82
NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
Alexandra Frazao, Louise Rethacker, Meriem Messaoudene, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 81
NK cells to cure cancer
Clara Di Vito, Joanna Mikulak, Elisa Zaghi, et al.
Seminars in Immunology (2019) Vol. 41, pp. 101272-101272
Closed Access | Times Cited: 81
Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle‐associated MICA: Dual role in cancer immunosurveillance
Elisabetta Vulpis, Luisa Loconte, Agnese Peri, et al.
Journal of Extracellular Vesicles (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 39
Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
Shayista Akbar, Afsheen Raza, Reyad Mohsin, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 26
Extracellular vesicles in tumor immunity: mechanisms and novel insights
Liwen Kuang, Lei Wu, Yongsheng Li
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Immunosurveillance and immunotherapy of tumors by innate immune cells
Alexandre Iannello, Thornton W. Thompson, Michele Ardolino, et al.
Current Opinion in Immunology (2015) Vol. 38, pp. 52-58
Open Access | Times Cited: 90
Page 1 - Next Page

Scroll to top